Kornimate/medical-research-clean huggingface dataset:
prochymal® (human adult stem cells) intravenous infusion following acute myocardial infarction (ami)

Conditions: Myocardial Infarction

Summary: the objective of the present study is to establish the safety and efficacy of prochymal® following first acute myocardial infarction.

the standard of care treatment for acute myocardial infarction (ami) usually includes immediate perfusion, optimal pain relief, oxygen, aspirin or other anti-coagulants, beta-blockers, nitrates and ace-inhibitors. however, because salvaging the viable myocardium is dependent on early reperfusion, only a minority of participants will reach the hospital within the time-window for myocardial rescue. thus, even if the participant manages their tobacco use, hypertension, lipid levels, diabetes, weight and exercise, many participants will go on to develop congestive heart failure (chf). though the medical management for chf may improve symptoms and slow disease progression, such treatment cannot restore a functioning myocardium. a therapy that could improve the myocardial remodeling process and reduce the incidence or severity of chf following acute mi would provide a significant benefit. the characteristics and biologic activity of prochymal®, along with a good safety profile in human trials to date, suggest that prochymal® may be a good candidate for addressing this unmet medical need.

Eligibility criteria:
inclusion criteria: * male or female between 21 and 85 years old, inclusive * first heart attack within 7 days prior to randomization and drug infusion * baseline left ventricular ejection fraction (lvef) 20-45% * hemodynamically stable within 24 hours prior to randomization * adequate pulmonary function exclusion criteria: * previous medical history of heart attack, heart failure, significant valvular heart disease, aortic dissection * pacemaker or other device * pregnant, breast-feeding, or intends to become pregnant during the study * allergy to cow or pig derived products * evidence of active malignancy or prior history of active malignancy * major surgical procedure or major trauma within the past 14 days * autoimmune disease (e.g., lupus, multiple sclerosis) * any medical condition, which in the opinion of the investigator, renders participation unsuitable * undergone pharmacologic cardioversion or external defibrillation within 24 hours of randomization. * experienced cardiac arrest more than 36 hours after presentation to site or within 24 hours of randomization.

Keywords: acute myocardial infarction ami myocardial infarction heart attack mesenchymal stem cells msc adult human stem cells osiris
effect of apple and apple pomace on inflammation and cholesterol metabolism in healthy overweight

Conditions: Cardiovascular Diseases

Summary: the investigators will assess the protective and antiinflammatory effects of processed fruit and fruit fibre in overweight subjects with signs of metabolic syndrome. a single-blinded parallel study is conducted to investigate the protective effects of fruit fibre on colonic epithelium. relevant signalling pathways related to cholesterol metabolism, vascular inflammation, oxidative defence, apoptosis and sterol metabolism will be targeted. volunteers are randomly assigned one of three groups. they are instructed to follow a polyphenol and pectin restricted diet for six weeks. the last four weeks in this six week period, the restricted diet is supplemented with whole apples (550g/day), apple pomace (22g/day) or nothing. blood, urine, faecal samples and colon biopsies are collected before and after the four weeks intervention period.


Eligibility criteria:
inclusion criteria: * healthy * bmi over 30 * no daily medication * not strenuous exercise \> 10hours/week * no blood donation 3 months before or during the study exclusion criteria: * smoking * simultaneous participation in other research projects * use of any dietary supplements

Keywords: apple apple pomace metabolomics gene expression lipid metabolism prevention antiinflammatory effect
real-world treatment patterns and outcomes among patients with chronic myeloid leukemia in earlier lines of therapy

Conditions: Chronic Myeloid Leukemia

Summary: this was a retrospective, non-interventional, observational cohort study using optum's de-identified clinformatics® data mart database. adult patients newly diagnosed with chronic myeloid leukemia (cml) treated with tyrosine kinase inhibitors (tkis) were identified using the optum database and classified into the following cohorts: * first treatment cohort: patients newly diagnosed with cml who received first treatment with a tki. * second treatment cohort: patients from first treatment cohort with a subsequent line of therapy (i.e., second treatment) with a tki. the observation period spanned from the start of data availability (i.e., 01 january 2007) to the earliest of end of data (i.e., 30 june 2022), end of continuous health plan enrollment, or death (if available). the index date was defined as the first treatment initiation for the first treatment tki cohort and as the second treatment initiation for the second treatment tki cohort. the baseline period consisted of the 6 months prior to the index date. the follow-up period started on the index date and ended at the earliest of end of observation period or hematopoietic stem cell transplantation (hsct).


Eligibility criteria:
inclusion criteria: * adult patients who initiated their first treatment with imatinib, dasatinib, nilotinib, or bosutinib (conditional on food and drug administration (fda) approval dates) with 6 months continuous health plan enrollment prior to the first prescription fill date. * patients with 2 or more diagnoses for cml (adult as of the first diagnosis for cml). * patients had index date on or after first cml diagnosis. * patients had no diagnoses for cml remission/relapse prior to index date. * patients had no gastrointestinal stomach tumor (gist) or chronic myelomonocytic leukemia (cmml) at any time. * patients had no medical claims associated with a clinical trial during the baseline period. * patients had no hematopoietic stem cell transplantation (hsct) during the baseline period. * patients had no cml-related chemotherapy treatments for accelerated phase (ap)/blast crisis (bc) during the baseline period. * first treatment cohort: * patients started first treatment for cml with imatinib, dasatinib, nilotinib, or bosutinib in 2012 or later. * patients had no hsct during the first treatment baseline period. * patients had no cml-related chemotherapy treatment for ap/bc during the first treatment baseline period. * second treatment cohort: * patients started second treatment for cml with imatinib, dasatinib, nilotinib, or bosutinib in 2012 or later. * patients had no hsct from the first treatment baseline period up to second treatment initiation. * patients had no cml-related chemotherapy treatment for ap/bc from the first treatment baseline period up to second treatment initiation.
norepinephrine in preperiod of hypotensive resuscitation in hemorrhagic shock

Conditions: Norepinephrine; Hemorrhagic Shock; Hypotensive Resuscitation

Summary: the aim of this work was to investigate the effects of low dose of norepinephrine in preperiod of hypotensive resuscitation in hemorrhagic shock.

hemorrhagic shock is one of the leading causes of death following trauma. new fluid resuscitation concepts, including hypotensive, hypothermic, and delayed resuscitation for uncontrolled hemorrhagic shock, have been put forward and obtained a good effect both in clinical and laboratory parameters. the 2019 european guideline on the management of major bleeding and coagulopathy following trauma recommends the use of norepinephrine (ne) for maintaining target arterial blood pressure in patients with life-threatening hypotension. ne has potent α-adrenergic receptor activation activity, which can stimulate α-1 adrenergic receptors on peripheral vascular smooth muscles. high-dose ne may result in excessive arteriolar vasoconstriction which subsequently leads to the disorder of microcirculation and tissue hypoxia.

Eligibility criteria:
inclusion criteria: * age ≥ 18 years old. * both sexes. * patients with hemorrhagic shock exclusion criteria: * patients with cardiac arrest at admission. * severe brain. * spinal injury (because of different target blood pressures). * death due to hemostatic failure within 6 h of admission. * pregnancy.
heartguide: preliminary study

Conditions: Cardiac Disease

Summary: echocardiography is the examination of choice for the study of cardiac pathologies. interest of echocardiography for other medical specialties has already been demonstrated (intensive care in the case of hemodynamic failure - in intra and extra hospital emergency medicine for the initial assessment of chest pain or dyspnea). the expansion of echocardiography'use has been catalyzed by miniaturization of echographic systems and decrease in their price. recently, probes directly connected to a tablet or phone have been developed at a limited cost. therefore, it's possible to consider these ultrasound scanners as the new stethoscope that could be used by any health professional. the last limit to this democratization is the training, especially for non-specialists (non-cardiologists).

since january 2019, echocardiography laboratory headed by prof. stéphane lafitte and deski (start-up - bordeaux) have been working on guiding non-experts through their cardiac ultrasound examination. an algorithm indicating in real time if the view obtained corresponds to a reference view has already been validated. however, this algorithm does not tell the operator which movement would improve the image quality. thanks to advances in deep learning and by combining cardiac ultrasound acquisitions with systems that record the position of the probes in real time, it would be possible to develop an algorithm able to guide the operator's movements.

Eligibility criteria:
inclusion criteria: * patients (male or female) older than 18 years, * patient having a scheduled cardiac ultrasound outside any emergency context, * patients who have not objected to participating in the research (at the latest on the day of inclusion and before any examination required by the research), * subjects affiliated or benefiting from a social security plan, * women of childbearing age who are using effective contraception. exclusion criteria: * person under legal protection (legal protection, guardianship or curatorship), * person deprived of liberty by judicial or administrative decision, * person who is unable to give his/her non-opposition, * pregnant or breastfeeding women.

Keywords: echocardiography guidance algorithm
folfox plus sir-spheres microspheres versus folfox alone in patients with liver mets from primary colorectal cancer

Conditions: Colorectal Cancer; Colorectal Carcinoma; Liver Metastases

Summary: this study is a randomized multi-center trial that will assess the effect of adding selective internal radiation therapy (sirt), using sir-spheres microspheres®, to a standard chemotherapy regimen of folfox as first line therapy in patients with non-resectable liver metastases from primary colorectal adenocarcinoma. treatment with the biologic agent bevacizumab, if part of the standard of care at participating institutions, is allowed within this study at the discretion of the treating investigator.


Eligibility criteria:
inclusion criteria: * unequivocal and measurable ct evidence of liver metastases which are not treatable by surgical resection or local ablation. * limited extra-hepatic metastases in the lung and/or lymph nodes are permitted (lung: 5 lesions total, \< 1 cm, or 1 single lesion of up to 1.7 cm; lymph nodules in one single anatomic area (pelvis, abdomen or chest): any number, \< 2 cm). * suitable for either treatment regimen. * prior chemotherapy for metastatic colorectal cancer is not allowed. * who performance status 0-1. * adequate hematological, renal and hepatic function. * age 18 years or older. * willing and able to provide written informed consent. * life expectancy of at least 3 months without any active treatment. exclusion criteria * evidence of ascites, cirrhosis, portal hypertension, main portal or venous tumor involvement or thrombosis as determined by clinical or radiologic assessment. * previous radiotherapy delivered to the upper abdomen. * non-malignant disease that would render the patient unsuitable for treatment according to the protocol. * peripheral neuropathy \> grade 1 (nci-ctc). * dose limiting toxicity with previous adjuvant 5-fu or oxaliplatin chemotherapy. * prior non-adjuvant chemotherapy for any malignancy. adjuvant chemotherapy for colorectal cancer is not an exclusion criteria provided that it was completed more than 6 months before entry into the study. * pregnant or breast-feeding. * other active malignancy.

Keywords: colon cancer colorectal carcinoma liver metastases sir-spheres microspheres yttrium-90 folfox bevacizumab metastatic colorectal cancer
correlation between coital activity during pregnancy and premature delivery related to prostanoid receptor polymorphisms

Conditions: Labor Onset; Gravidity

Summary: the purpose of our study is correlate between premature delivery (between week 23-35 of the pregnancy) in women that had intercourse up to 12 hours prior to beginning of labor and polymorphisms in the gene prostanoid receptor.

during the past years there has been a conflict between different studies regarding the correlation between intercourse during pregnancy and early labor. brustman et al showed that women that were at a high risk for early delivery and had intercourse and then an early labor had significantly increase uterine activity compared to women at low risk. petridou et al showed that this risk is significantly higher at week 33 of gestation. however, the cochrane library summary leaves the question of correlation between intercourse and early labor unanswered. in sayle et al's study showed no correlation between early delivery and intercourse. in 2004 oguma described 3 polymorphisms in the prostanoid receptor gene. these polymorphisms were correlated to increased activity of smooth muscles of bronchi in asthma. since this gene is also expressed in the uterine muscles we wanted to determine whether there is a correlation between the three polymorphisms t-549c, c-441t, t-197c, g+1044a and early delivery due to intercourse. 1. brustman ls, raptoulis m. langer o, anyaegbunam a \& merkatz ir. changes in the pattern of uterine contractility in relationship to coitus during pregnancies at low and high risk for preterm labor. obstet gynecol 1989;73:166-168 2. petridou e, salvnos h, skalkidou a, dessypris n, moustaki m \& trichopoulos d. are there common triggers of preterm deliveries. british j obst gynecol 2001;108:598-604) 3. kavanagh j, kelly aj \& thomas j. sexual intercourse for cervical ripening and induction of labour. the cochrane database of systematic reviews 2001, issuse 2.art. no.:cd003093. doi: 10.1002/14651858.cd003093 4. sayle ae, savitz da, thorp jm, hertz-picciotto i \& wilcox aj. sexual activity during late pregnancy and risk of preterm delivery. obstet gynecol 2001;97:283-9) 5. bernal al. mechanisms of labour-biochemical aspects. bjog 2003;110(supp 20):39-45 6. oguma t, palmer l, birden e, sonna la, asano k\& lilly cm. role of prostanoid dp receptor variants in susceptibility to asthma. nejm 2004;351:1752-63

Eligibility criteria:
inclusion criteria: * women who start delivery in weeks 23-35 of pregnancy 12 hours after intercourese. * women who come for delivery after week 31 and have not had intercourse during the previous month. * women at term who have been sexually active during their pregnancy. exclusion criteria: * any other women who come in for delivery.
effect of human urinary kallidinogenase on inflammatory factors in acute ischemic stroke (kif-ais)

Conditions: Acute Ischemic Stroke

Summary: the goal of this clinical trial is to explore the changes in the expression levels of inflammatory factors before and after the early treatment of human urinary kallidinogen (huk) in the acute ischemic stroke. it will also learn about the correlation between inflammatory factors and ais prognosis, in order to clarify the efficacy and safety of urinary kallidinogen in the acute phase of ais.

the study process lasts for a total of 90 days, including the screening period, treatment period, and follow-up period. during the treatment period, the experimental group is treated with huk in the 48 hours of ais plus routine clinical treatment, while the control group receives routine clinical treatment group for 7 days.all patients are followed up until the 90th day after stroke. the sample size of the study is 200 patients. the ratio of the experimental group to the control group was 1:1.

Eligibility criteria:
inclusion criteria: 1. diagnosis as acute ischemic stroke according to the chinese guidelines for diagnosis and treatment of acute ischemic stroke 2018; 2. first clinical onset or previous presence of cerebral infarction without severe sequelae（premorbid mrs ≤2） 3. age≥18 years, male or female; 4. 3≤baseline nihss≤25; 5. written informed consent obtained from the patient or legally responsible person. exclusion criteria: 1. cerebral hemorrhage and the acute phase of other hemorrhagic diseases； 2. previously allergic or intolerant to injectable huk； 3. used acei drugs prior to medication and less than 5 half-lives of the drug (according to the specific drug instructions) or received acei drugs during the study period; 4. stent surgery after the ais onset or planned interventional therapy; 5. pregnancy, lactation or planned pregnancy； 6. life expectancy of less than 3months or inability to complete the study for other reasons； 7. unwilling to be followed up or poor compliance； 8. current participation in other clinical research; 9. other causes of ais (such as dissection, vasculitis, pre-thrombotic lesions, drug abuse).

Keywords: acute ischemic stroke urinary kallidinogen inflammatory factors 90 days functional outcomes
studying electromyographic activity in patients with upper limb amputations

Conditions: Amputation, Traumatic

Summary: the primary purpose of this study is to determine the extent to which the regenerative peripheral nerve interface ( i.e. reinnervation of partial muscle grafts by residual peripheral nerves) enables both the generation of high-performance motor control signals for prosthetic limbs, and the input of sensory percepts by electrical stimulation.


Eligibility criteria:
inclusion criteria: * for the prosthetic control graft arm: * must have previously undergone upper limb amputation * must be otherwise healthy (e.g. no severe pain syndromes or untreated mental health disorders) * must be american society of anesthesiologists (asa) class i (low surgical risk) * must have sufficient soft tissue quality to support performance of the operative procedures * must have not previously received the partial muscle graft surgery * for the neuroma graft arm: * must have previously undergone upper limb amputation * must be otherwise healthy (e.g. no severe pain syndromes or untreated mental health disorders) * must have previously received the partial muscle graft surgery * for the able-bodied arm: * must have not undergone upper limb amputation * must be in good health exclusion criteria: * for the prosthetic control graft arm: * participants sustaining severe crushing or avulsion injuries with substantial superficial and deep scarring, may not be appropriate candidates for inclusion in the study * for the able-bodied arm: * participants with a history of nerve pain may not be appropriate candidates for inclusion in the study
population pharmacokinetics in benznidazole-treated adults with chronic with chagas disease

Conditions: Chagas Disease

Summary: o study population pharmacokinetics in benznidazole-treated adult patients with chronic chagas disease to get information to optimize drug doses.


Eligibility criteria:
inclusion criteria: * adult patients with chronic chagas disease diagnosed by 2 different and positive serological tests. * patients with chronic chagas disease who are going to start treatment with benznidazole. * any gender. * all the participants must agree to participate in the study and must sign the informed consent. exclusion criteria: * patients younger than 18. * patients with previous hypersensitivity to benznidazole. * immunocompromised patients as aids, cancer, chemotherapy, longterm corticoids need, primary immunodeficiency, or any other. * hepatic dysfunction * renal dysfunction: serum creatinin higher than 3 mg/dl. * pregnancy or lactation. * low adhesion to treatment or check-up. * impossibility of follow-up. * severe adverse reaction to benznidazole. * any other situation that could be risky for the patient.
pilot internet-based self-help program for managing corona (covid-19) stress

Conditions: Stress; Stress, Psychological

Summary: the current study examines an adapted guided self-help stress reduction program, focusing on reducing stress in the time of covid-19. two studies are planned: 1) an international study in english in which individuals proficient in english throughout the world will participate and 2) a follow-up study in hebrew.

the current study examines an adapted guided self-help stress reduction program, focusing on reducing stress in the time of covid-19. two studies are proposed: 1) an international study in english in which individuals proficient in english throughout the world will participate and 2) a study in hebrew. the first study will publicize via social media and participants will be randomized to either immediate participation or a 6 week waitlist period. assessments will be conducted pre, (again after waitlist for the control group), posttx (after completion/cessation of the program), 6 month and 1 year followup. two forms of assessment will be conducted: pre-post-follow-up (with the crisis measure) and weekly during the program (via the dass-21). for the full program see: https://www.iterapi.se/sites/coronastress/

Eligibility criteria:
inclusion criteria: * read/write english, * feels stress due to corona/covid-19 exclusion criteria: * current psychological or psychiatric treatment, * current psychiatric illness, * suicidality, * psychosis, * bipolar, * severe dissociative symptoms, * in a currently severe traumatic situation, * having a serious medical illness.